DBusiness
Karmanos Cancer Institute in Detroit will be the first provider to offer the TheraBionic P1 medical device for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer. Boris Pasche, M.D., Ph.D., FACP, president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D., medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team, explain the device's benefits to patients 18 years and older who have failed first- and second-line therapies.
Read the article here.
Boris Pasche, M.D., Ph.D., FACP
Anthony Shields, M.D., Ph.D.